Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Teva
Healthtrust
Novartis
Harvard Business School
Express Scripts
Daiichi Sankyo
AstraZeneca
McKinsey
Queensland Health

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,700,550

« Back to Dashboard

Which drugs does patent 7,700,550 protect, and when does it expire?

Patent 7,700,550 protects VIBATIV and is included in one NDA.

This patent has eighty-eight patent family members in thirty-four countries.
Summary for Patent: 7,700,550
Title:Glycopeptide phosphonate derivatives
Abstract:Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents.
Inventor(s): Leadbetter; Michael R. (San Leandro, CA)
Assignee: Theravance, Inc. (South San Francisco, CA)
Application Number:11/977,429
Patent Claim Types:
see list of patent claims
Use; Delivery;

Drugs Protected by US Patent 7,700,550

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-001 Sep 11, 2009 DISCN Yes No ➤ Sign Up ➤ Sign Up METHOD OF TREATING BACTERIAL INFECTIONS ➤ Sign Up
Theravance Biopharma VIBATIV telavancin hydrochloride POWDER;IV (INFUSION) 022110-002 Sep 11, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF TREATING BACTERIAL INFECTIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,700,550

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,067,483 Pharmaceutical compositions containing a gycopeptide antibiotic and a cyclodextrin ➤ Sign Up
7,244,705 Polyacid glycopeptide derivatives ➤ Sign Up
6,620,781 Glycopeptide carboxy-saccharide derivatives ➤ Sign Up
6,828,299 Polyhydroxy glycopeptide derivatives ➤ Sign Up
6,887,976 Glycopeptide phosphonate derivatives ➤ Sign Up
8,101,575 Glycopeptide phosphonate derivatives ➤ Sign Up
7,265,086 Glycopeptide carboxy-saccharide derivatives ➤ Sign Up
7,026,288 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin ➤ Sign Up
6,831,150 Reductive alkylation process ➤ Sign Up
6,872,701 Glycopeptide phosphonate derivatives ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,700,550

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Ukraine 75083 ➤ Sign Up
Taiwan I305209 ➤ Sign Up
Slovakia 287470 ➤ Sign Up
Slovakia 18522002 ➤ Sign Up
Slovenia 1292612 ➤ Sign Up
Slovenia 1278549 ➤ Sign Up
Slovenia 1276759 ➤ Sign Up
Serbia 50499 ➤ Sign Up
Yugoslavia 96902 ➤ Sign Up
Portugal 1292612 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fuji
Express Scripts
Medtronic
McKinsey
Teva
Johnson and Johnson
Julphar
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot